Antimuscarinic antibodies in Sjögren's syndrome: Where are we, and where are we going?

Arthritis and Rheumatism

Volumn 52, Issue 10, 2005, Pages 2984-2995

  Dawson, Luke ^a   Tobin, Andrew ^a   Smith, Peter ^a   Gordon, Tom ^b  

^a UNIVERSITY OF LIVERPOOL   (United Kingdom)

^b FLINDERS MEDICAL CENTRE   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

4 DIPHENYLACETOXY 1 METHYLPIPERIDINE; AUTOANTIBODY; CALCIUM ION; CHLORIDE ION; DARIFENACIN; G PROTEIN COUPLED RECEPTOR; IDIOTYPIC ANTIBODY; IMMUNOGLOBULIN; IMMUNOGLOBULIN A; IMMUNOGLOBULIN G; METHOCTRAMINE; MUSCARINIC M1 RECEPTOR; MUSCARINIC M2 RECEPTOR; MUSCARINIC M3 RECEPTOR; MUSCARINIC M4 RECEPTOR; MUSCARINIC M5 RECEPTOR; MUSCARINIC RECEPTOR; MUSCARINIC RECEPTOR BLOCKING AGENT; N [2 [2 (DIPROPYLAMINOMETHYL) 1 PIPERIDYL]ETHYL] 5,11 DIHYDRO 6 OXO 6H PYRIDO[2,3 B][1,4]BENZODIAZEPINE 11 CARBOXAMIDE; PIRENZEPINE; RECEPTOR SUBTYPE; SODIUM CHLORIDE; SODIUM ION;

ACINAR CELL; ANTIBODY SPECIFICITY; AUTOIMMUNE DISEASE; AUTOIMMUNITY; AUTONOMIC DYSFUNCTION; ENZYME LINKED IMMUNOSORBENT ASSAY; HUMAN; LACRIMAL GLAND; LIGAND BINDING; MOLECULAR CLONING; MULTIGENE FAMILY; NONHUMAN; NUCLEOTIDE SEQUENCE; PATHOGENESIS; PRIORITY JOURNAL; RECEPTOR GENE; REVIEW; SALIVARY GLAND; SECRETION; SJOEGREN SYNDROME; WESTERN BLOTTING;

AUTOANTIBODIES; HUMANS; RECEPTORS, MUSCARINIC; SJOGREN'S SYNDROME;

EID: 26844506257     PISSN: 00043591     EISSN: None     Source Type: Journal    
DOI: 10.1002/art.21347     Document Type: Review

References (94)

1. Tyldesley WR, Field EA. Oral medicine. Oxford: Oxford University Press; 1995.
2. Humphreys-Beher MG, Brayer J, Yamachika S, Peck AB, Jonsson R. An alternative perspective to the immune response in autoimmune exocrinopathy: induction of functional quiescence rather than destructive autoaggression. Scand J Immunol 1999;49:7-10.
3. Fox PC, Speight PM. Current concepts of autoimmune exocrinopathy: immunologic mechanisms in the salivary pathology of Sjogren's syndrome. Crit Rev Oral Biol Med 1996;7:144-58.
4. Dawson LJ, Smith PM, Moots RJ, Field EA. Sjogren's syndrome: time for a new approach. Rheumatology (Oxford) 2000;39:234-7.
5. Dawson LJ, Field EA, Harmer AR, Smith PM. Acetylcholine-evoked calcium mobilization and ion channel activation in human labial gland acinar cells from patients with primary Sjogren's syndrome. Clin Exp Immunol 2001;124:480-5.
6. Pedersen AM, Dissing S, Fahrenkrug J, Hannibal J, Reibel J, Nauntofte B. Innervation pattern and Ca2+ signalling in labial salivary glands of healthy individuals and patients with primary Sjogren's syndrome (pSS). J Oral Pathol Med 2000;29:97-109.
7. Heft MW, Baum BJ. Unstimulated and stimulated parotid salivary flow rate in individuals of different ages. J Dent Res 1984;63: 1182-5.
8. Ship JA, Baum BJ. Is reduced salivary flow normal in old people? [letter]. Lancet 1990;336:1507.
9. Scott J. Qualitative and quantitative observations on the histology of human labial salivary glands obtained post mortem. J Biol Buccale 1980;8:187-200.
10. Jonsson R, Haga HJ, Gordon TP. Current concepts on diagnosis, autoantibodies and therapy in Sjogren's syndrome. Scand J Rheumatol 2000;29:341-8.
11. Drachman DB. Myasthenia gravis. N Engl J Med 1994;330: 1797-810.
12. Weetman AP. Graves' disease. N Engl J Med 2000;343:1236-48.
13. Gordon TP, Bolstad AI, Rischmueller M, Jonsson R, Waterman SA. Autoantibodies in primary Sjogren's syndrome: new insights into mechanisms of autoantibody diversification and disease pathogenesis. Autoimmunity 2001;34:123-32.
14. Bacman S, Sterin-Borda L, Camusso JJ, Arana R, Hubscher O, Borda E. Circulating antibodies against rat parotid gland M3 muscarinic receptors in primary Sjogren's syndrome. Clin Exp Immunol 1996;104:454-9.
15. Waterman SA, Gordon TP, Rischmueller M. Inhibitory effects of muscarinic receptor autoantibodies on parasympathetic neurotransmission in Sjögren's syndrome. Arthritis Rheum 2000;43: 1647-54.
16. Dawson LJ, Allison HE, Stanbury J, Fitzgerald D, Smith PM. Putative anti-muscarinic antibodies cannot be detected in patients with primary Sjogren's syndrome using conventional immunological approaches. Rheumatology (Oxford) 2004;43:1488-95.
17. Dawson LJ, Holt DJ, Higham SM, Longman LP, Field EA. A comparison of salivary gland hypofunction in primary and secondary Sjogren's syndrome. Oral Dis 2001;7:28-30.
18. Leppilahti M, Tammela TL, Huhtala H, Kiilholma P, Leppilahti K, Auvinen A. Interstitial cystitis-like urinary symptoms among patients with Sjogren's syndrome: a population-based study in Finland. Am J Med 2003;115:62-5.
19. Walker J, Gordon T, Lester S, Downie-Doyle S, McEvoy D, Pile K, et al. Increased severity of lower urinary tract symptoms and daytime somnolence in primary Sjogren's syndrome. J Rheumatol 2003;30:2406-12.
20. Rosztoczy A, Kovacs L, Wittmann T, Lonovics J, Pokorny G. Manometric assessment of impaired esophageal motor function in primary Sjogren's syndrome. Clin Exp Rheumatol 2001;19:147-52.
21. Kovacs L, Torok T, Bari F, Keri Z, Kovacs A, Makula E, et al. Impaired microvascular response to cholinergic stimuli in primary Sjogren's syndrome. Ann Rheum Dis 2000;59:48-53.
22. Bachmeyer C, Zuber M, Dupont S, Blanche P, Dhote R, Mas JL. Adie syndrome as the initial sign of primary Sjogren syndrome. Am J Ophthalmol 1997;123:691-2.
23. Tumiati B, Perazzoli F, Negro A, Pantaleoni M, Regolisti G. Heart rate variability in patients with Sjogren's syndrome. Clin Rheumatol 2000;19:477-80.
24. Birdsall NJ, Hulme EC, Stockton J, Burgen AS, Berrie CP, Hammer R, et al. Muscarinic receptor subclasses: evidence from binding studies. Adv Biochem Psychopharmacol 1983;37:323-9.
25. Kubo T, Maeda A, Sugimoto K, Akiba I, Mikami A, Takahashi H, et al. Primary structure of porcine cardiac muscarinic acetylcholine receptor deduced from the cDNA sequence. FEBS Lett 1986;209:367-72.
26. Kubo T, Fukuda K, Mikami A, Maeda A, Takahashi H, Mishina M, et al. Cloning, sequencing and expression of complementary DNA encoding the muscarinic acetylcholine receptor. Nature 1986;323:411-6.
27. Bonner TI. New subtypes of muscarinic acetylcholine receptors [review]. Trends Pharmacol Sci 1989;Suppl:11-5.
28. Peralta EG, Ashkenazi A, Winslow JW, Smith DH, Ramachandran J, Capon DJ. Distinct primary structures, ligand-binding properties and tissue-specific expression of four human muscarinic acetylcholine receptors. EMBO J 1987;6:3923-9.
29. Bonner TI, Buckley NJ, Young AC, Brann MR. Identification of a family of muscarinic acetylcholine receptor genes. Science 1987;237:527-32.
30. Caulfield MP, Birdsall NJ. International Union of Pharmacology. XVII. Classification of muscarinic acetylcholine receptors. Pharmacol Rev 1998;50:279-90.
31. Dai YS, Ambudkar IS, Horn VJ, Yeh CK, Kousvelari EE, Wall SJ, et al. Evidence that M3 muscarinic receptors in rat parotid gland couple to two second messenger systems. Am J Physiol 1991;261:C1063-73.
32. Bockman CS, Bradley ME, Dang HK, Zeng W, Scofield MA, Dowd FJ. Molecular and pharmacological characterization of muscarinic receptor subtypes in a rat parotid gland cell line: comparison with native parotid gland. J Pharmacol Exp Ther 2001;297:718-26.
33. Li M, Yasuda RP, Wall SJ, Wellstein A, Wolfe BB. Distribution of m2 muscarinic receptors in rat brain using antisera selective for m2 receptors. Mol Pharmacol 1991;40:28-35.
34. Wall SJ, Yasuda RP, Li M, Wolfe BB. Development of an antiserum against m3 muscarinic receptors: distribution of m3 receptors in rat tissues and clonal cell lines. Mol Pharmacol 1991;40:783-9.
35. Wall SJ, Yasuda RP, Hory F, Flagg S, Martin BM, Ginns EI, et al. Production of antisera selective for m1 muscarinic receptors using fusion proteins: distribution of m1 receptors in rat brain. Mol Pharmacol 1991;39:643-9.
36. Tobin AB, Nahorski SR. Rapid agonist-mediated phosphorylation of m3-muscarinic receptors revealed by immunoprecipitation. J Biol Chem 1993;268:9817-23.
37. Budd DC, McDonald JE, Tobin AB. Phosphorylation and regulation of a Gq/11-coupled receptor by casein kinase 1α. J Biol Chem 2000;275:19667-75.
38. Benovic JL, Shorr RG, Caron MG, Lefkowitz RJ. The mammalian β2-adrenergic receptor: purification and characterization. Biochemistry 1984;23:4510-8.
39. Smith RD, Hunyady L, Olivares-Reyes JA, Mihalik B, Jayadev S, Catt KJ. Agonist-induced phosphorylation of the angiotensin AT1a receptor is localized to a serine/threonine-rich region of its cytoplasmic tail. Mol Pharmacol 1998;54:935-41.
40. Lutz MP, Pinon DI, Gates LK, Shenolikar S, Miller LJ. Control of cholecystokinin receptor dephosphorylation in pancreatic acinar cells. J Biol Chem 1993;268:12136-42.
41. Roush ED, Warabi K, Kwatra MM. Characterization of differences between rapid agonist-dependent phosphorylation and phorbol ester-mediated phosphorylation of human substance P receptor in intact cells. Mol Pharmacol 1999;55:855-62.
42. Hawtin SR, Tobin AB, Patel S, Wheatley M. Palmitoylation of the vasopressin V1a receptor reveals different conformational requirements for signaling, agonist-induced receptor phosphorylation, and sequestration. J Biol Chem 2001;276:38139-46.
43. Van Koppen CJ, Nathanson NM. Site-directed mutagenesis of the m2 muscarinic acetylcholine receptor: analysis of the role of N-glycosylation in receptor expression and function. J Biol Chem 1990;265:20887-92.
44. Smith PM. Mechanisms of secretion by salivary glands. In: O'Mullane D, editor. Saliva and oral health. London: British Dental Journal; 1996. p. 9-25.
45. Nakamura T, Matsui M, Uchida K, Futatsugi A, Kusakawa S, Matsumoto N, et al. M(3) muscarinic acetylcholine receptor plays a critical role in parasympathetic control of salivation in mice. J Physiol 2004;558:561-75.
46. Matsui M, Motomura D, Karasawa H, Fujikawa T, Jiang J, Komiya Y, et al. Multiple functional defects in peripheral autonomic organs in mice lacking muscarinic acetylcholine receptor gene for the M3 subtype. Proc Natl Acad Sci U S A 2000;97: 9579-84.
47. Kidd JF, Thorn P. Intracellular Ca2+ and Cl- channel activation in secretory cells. Annu Rev Physiol 2000;62:493-513.
48. Straub SV, Wagner LE II, Bruce JI, Yule DI. Modulation of cytosolic calcium signaling by protein kinase A-mediated phosphorylation of inositol 1,4,5-trisphosphate receptors. Biol Res 2004;37:593-602.
49. Young JA, van Lennep EW. The morphology of salivary glands. New York: Academic Press; 1978.
50. Harmer AR, Smith PM, Gallacher DV. Local and global calcium signals and fluid and electrolyte secretion in mouse submandibular acinar cells. Am J Physiol Gastrointest Liver Physiol 2005;288:G118-24.
51. Harmer AR, Gallacher DV, Smith PM. Correlations between the functional integrity of the endoplasmic reticulum and polarized Ca2+ signalling in mouse lacrimal acinar cells: a role for inositol 1,3,4,5-tetrakisphosphate. Biochem J 2002;367:137-43.
52. Fogarty KE, Kidd JF, Turner A, Skepper JN, Carmichael J, Thorn P. Microtubules regulate local Ca2+ spiking in secretory epithelial cells. J Biol Chem 2000;275:22487-94.
53. Berridge MJ. Elementary and global aspects of calcium signalling. J Physiol 1997;499:291-306.
54. Bezprozvanny I, Watras J, Ehrlich BE. Bell-shaped calcium-response curves of Ins(1,4,5)P3- and calcium-gated channels from endoplasmic reticulum of cerebellum. Nature 1991;351:751-4.
55. Tinel H, Cancela JM, Mogami H, Gerasimenko JV, Gerasimenko OV, Tepikin AV, et al. Active mitochondria surrounding the pancreatic acinar granule region prevent spreading of inositol trisphosphate-evoked local cytosolic Ca(2+) signals. EMBO J 1999;18:4999-5008.
56. Konttinen YT, Platts LA, Tuominen S, Eklund KK, Santavirta N, Tornwall J, et al. Role of nitric oxide in Sjögren's syndrome. Arthritis Rheum 1997;40:875-83.
57. Beroukas D, Goodfellow R, Hiscock J, Jonsson R, Gordon TP, Waterman SA. Dp-regulation of M3-muscarinic receptors in labial salivary gland acini in primary Sjogren's syndrome. Lab Invest 2002;82:203-10.
58. Zoukhri D, Hodges RR, Rawe IM, Dartt DA. Ca2+ signaling by cholinergic and α1-adrenergic agonists is up-regulated in lacrimal and submandibular glands in a murine model of Sjogren's syndrome. Clin Immunol Immunopathol 1998;89:134-40.
59. Mignogna MD, Fedele S, Lo Russo L, Lo Muzio L. Sialorrhoea as early oral clinical manifestation of primary Sjogren's syndrome? Rheumatology (Oxford) 2003;42:1113-4.
60. Ehlert FJ, Ostrom RS, Sawyer GW. Subtypes of the muscarinic receptor in smooth muscle. Life Sci 1997;61:1729-40.
61. Stengel PW, Gomeza J, Wess J, Cohen ML. M(2) and M(4) receptor knockout mice: muscarinic receptor function in cardiac and smooth muscle in vitro. J Pharmacol Exp Ther 2000;292: 877-85.
62. Goldblatt F, Gordon TP, Waterman SA. Antibody-mediated gastrointestinal dysmotility in scleroderma. Gastroenterology 2002; 123:1144-50.
63. Cavill D, Waterman SA, Gordon TP. Antibodies raised against the second extracellular loop of the human muscarinic M3 receptor mimic functional autoantibodies in Sjogren's syndrome. Scand J Immunol 2004;59:261-6.
64. Cavill D, Waterman SA, Gordon TP. Antiidiotypic antibodies neutralize autoantibodies that inhibit cholinergic neurotransmission. Arthritis Rheum 2003;48:3597-602.
65. Smith AJ, Jackson MW, Wang F, Cavill D, Rischmueller M, Gordon TP. Neutralization of muscarinic receptor autoantibodies by intravenous immunoglobulin in Sjogrens syndrome. Hum Immunol 2005;66:411-6.
66. Wang F, Jackson MW, Maughan V, Cavill D, Smith AJ, Waterman SA, et al. Passive transfer of Sjögren's syndrome IgG produces the pathophysiology of overactive bladder. Arthritis Rheum 2004;50: 3637-45.
67. Gudbjornsson B, Hedenstrom H, Stalenheim G, Hallgren R. Bronchial hyperresponsiveness to methacholine in patients with primary Sjogren's syndrome. Ann Rheum Dis 1991;50:36-40.
68. Drachman DB. Autonomic "myasthenia": the case for an autoimmune pathogenesis. J Clin Invest 2003;111:797-9.
69. Van Blokland SC, Versnel MA. Pathogenesis of Sjogren's syndrome: characteristics of different mouse models for autoimmune exocrinopathy. Clin Immunol 2002;103:111-24.
70. Yamamoto H, Sims NE, Macauley SP, Nguyen KH, Nakagawa Y, Humphreys-Beher MG. Alterations in the secretory response of non-obese diabetic (NOD) mice to muscarinic receptor stimulation. Clin Immunol Immunopathol 1996;78:245-55.
71. Robinson CP, Brayer J, Yamachika S, Esch TR, Peck AB, Stewart CA, et al. Transfer of human serum IgG to nonobese diabetic Igμ null mice reveals a role for autoantibodies in the loss of secretory function of exocrine tissues in Sjogren's syndrome. Proc Natl Acad Sci U S A 1998;95:7538-43.
72. Nguyen KH, Brayer J, Cha S, Diggs S, Yasunari U, Hilal G, et al. Evidence for antimuscarinic acetylcholine receptor antibody-mediated secretory dysfunction in NOD mice. Arthritis Rheum 2000;43:2297-306.
73. Bacman S, Perez Leiros C, Sterin-Borda L, Hubscher O, Arana R, Borda E. Autoantibodies against lacrimal gland M3 muscarinic acetylcholine receptors in patients with primary Sjogren's syndrome. Invest Ophthalmol Vis Sci 1998;39:151-6.
74. Berra A, Sterin-Borda L, Bacman S, Borda E. Role of salivary IgA in the pathogenesis of Sjogren syndrome. Clin Immunol 2002;104: 49-57.
75. Wang HY, Zeng SJ, Qiu PX. Development of muscarinic m3 and m4 receptor antibodies with pharmacological activities. Zhongguo Yao Li Xue Bao 1998;19:523-6.
76. Watson EL, Abel PW, DiJulio D, Zeng W, Makoid M, Jacobson KL, et al. Identification of muscarinic receptor subtypes in mouse parotid gland. Am J Physiol 1996;271:C905-13.
77. Hulme EC, Birdsall NJ, Buckley NJ. Muscarinic receptor subtypes. Annu Rev Pharmacol Toxicol 1990;30:633-73.
78. Bacman SR, Berra A, Sterin-Borda L, Borda ES. Human primary Sjogren's syndrome autoantibodies as mediators of nitric oxide release coupled to lacrimal gland muscarinic acetylcholine receptors. Curr Eye Res 1998;17:1135-42.
79. Bacman S, Berra A, Sterin-Borda L, Borda E. Muscarinic acetylcholine receptor antibodies as a new marker of dry eye Sjogren syndrome. Invest Ophthalmol Vis Sci 2001;42:321-7.
80. Cavill D, Waterman SA, Gordon TP. Failure to detect antibodies to extracellular loop peptides of the muscarinic M3 receptor in primary Sjogren's syndrome. J Rheumatol 2002;29:1342-4.
81. Chen CR, Tanaka K, Chazenbalk GD, McLachlan SM, Rapoport B. A full biological response to autoantibodies in Graves' disease requires a disulfide-bonded loop in the thyrotropin receptor N terminus homologous to a laminin epidermal growth factor-like domain. J Biol Chem 2001;276:14767-72.
82. Chazenbalk GD, Wang Y, Guo J, Hutchinson JS, Segal D, Jaume JC, et al. A mouse monoclonal antibody to a thyrotropin receptor ectodomain variant provides insight into the exquisite antigenic conformational requirement, epitopes and in vivo concentration of human autoantibodies. J Clin Endocrinol Metab 1999;84:702-10.
83. Gao J, Cha S, Jonsson R, Opalko J, Peck AB. Detection of anti-type 3 muscarinic acetylcholine receptor autoantibodies in the sera of Sjögren's syndrome patients by use of a transfected cell line assay. Arthritis Rheum 2004;50:2615-21.
84. Li J, Ha YM, Ku NY, Choi SY, Lee SJ, Oh SB, et al. Inhibitory effects of autoantibodies on the muscarinic receptors in Sjogren's syndrome. Lab Invest 2004;84:1430-8.
85. Jahn K, Franke C, Bufler J. Mechanism of block of nicotinic acetylcholine receptor channels by purified IgG from seropositive patients with myasthenia gravis. Neurology 2000;54:474-9.
86. Hoch W, McConville J, Helms S, Newsom-Davis J, Melms A, Vincent A. Auto-antibodies to the receptor tyrosine kinase MuSK in patients with myasthenia gravis without acetylcholine receptor antibodies. Nat Med 2001;7:365-8.
87. Drachman DB. How to recognize an antibody-mediated autoimmune disease: criteria. Res Publ Assoc Res Nerv Ment Dis 1990;68:183-6.
88. Rose NR, Bona C. Defining criteria for autoimmune diseases (Witebsky's postulates revisited). Immunol Today 1993;14:426-30.
89. Witebsky E, Rose NR, Terplan K, Paine JR, Egan RW. Chronic thyroiditis and autoimmunization. J Am Med Assoc 1957;164: 1439-47.
90. Nagaraju K, Cox A, Casciola-Rosen L, Rosen A. Novel fragments of the Sjögren's syndrome autoantigens α-fodrin and type 3 muscarinic acetylcholine receptor generated during cytotoxic lymphocyte granule-induced cell death. Arthritis Rheum 2001;44: 2376-86.
91. Dawson LJ, Caulfield VL, Stanbury JB, Field AE, Christmas SE, Smith PM. Hydroxychloroquine therapy in patients with primary Sjogren's syndrome may improve salivary gland hypofunction by inhibition of glandular cholinesterase. Rheumatology (Oxford) 2005;44:449-55.
92. Dawson LJ, Christmas SE, Smith PM. An investigation of interactions between the immune system and stimulus-secretion coupling in mouse submandibular acinar cells: a possible mechanism to account for reduced salivary flow rates associated with the onset of Sjogren's syndrome. Rheumatology (Oxford) 2000;39: 1226-33.
93. Tsubota K, Hirai S, King LS, Agre P, Ishida N. Defective cellular trafficking of lacrimal gland aquaporin-5 in Sjogren's syndrome. Lancet 2001;357:688-9.
94. Beroukas D, Hiscock J, Jonsson R, Waterman SA, Gordon TP. Subcellular distribution of aquaporin 5 in salivary glands in primary Sjogren's syndrome. Lancet 2001;358:1875-6.